Compare Garmin Ltd. (GRMN) vs Heron Therapeutics Inc (HRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Garmin Ltd. vs Heron Therapeutics Inc — how do they compare? Garmin Ltd. trades at $271.28 (market cap $53.26B), while Heron Therapeutics Inc trades at $0.37 (market cap $74.04M). The key difference: Garmin Ltd. is far larger — about 719.3× Heron Therapeutics Inc's market cap, and Garmin Ltd. pays a 1.52% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Garmin Ltd. for 83 Days and Heron Therapeutics Inc for 35 Days on average.
| GRMN | HRTX | |
|---|---|---|
Market Cap | $53.26B | $74.04M |
Volume | 529,054 | 3,668,095 |
Sector | Technology | Health |
52-Week High | $313.16 | $1.49 |
52-Week Low | $187.10 | $0.27 |
Typical Hold Time | 83 Days | 35 Days |
Enterprise Value | $50.77B | $180.78M |
Dividend Yield | 1.52% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Garmin (GRMN) trades at $268.44, down 3.86% on the day, amid a broader bearish technical signal. The company demonstrates strong fundamentals with consistent earnings beats, including Q2 2026 EPS of $2.81 beating estimates of $2.30. Revenue growth remains robust, rising from $4.9B in 2022 to $7.25B in 2025, with net income margins above 20%. Recent positive developments include multiple product awards and new feature rollouts across marine, automotive, and fitness segments.
Garmin presents a compelling investment case with strong profitability and consistent execution, though near-term technical pressure and cautious analyst sentiment (71% hold rating) suggest potential volatility. The consensus price target of $320.25 implies 19% upside, but investors should monitor competitive pressures in the wearable tech space and macroeconomic factors affecting consumer discretionary spending.
HRTX trades at $0.39, up 17.58% today, with a bullish technical signal from moving averages. The company reported Q2 2026 revenue of $37.7 million but missed EPS estimates with a $0.03 loss. Despite negative profitability metrics, analyst consensus remains strongly positive with 89% buy ratings. Recent news highlights ongoing comparisons with peers and earnings performance discussions.
The outlook is mixed: strong analyst support and technical momentum suggest potential upside, but persistent losses and high valuation ratios pose significant risks. Investment opportunity hinges on revenue growth translating to profitability, while key risks include execution challenges and competitive pressures in the biotechnology sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Garmin Ltd.
Garmin produces GPS-enabled hardware and software for five verticals: fitness, outdoors, auto, aviation, and marine. The company relies on licensing mapping data to enable its hardware specialized for often niche activities like scuba diving or sailing. Garmin operates in 100 countries and sells its products via distributors as well as relationships with original equipment manufacturers.
Read more on GRMN →About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →
